Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory disease

Authors:
  • NTNaomi Tsurikisawa
    Naomi Tsurikisawa
  • SNShinichi Nogi
    Shinichi Nogi
  • KIKanako Iwata
    Kanako Iwata
  • COChiyako Oshikata
    Chiyako Oshikata
  • STSayaka Tatsuno
    Sayaka Tatsuno
  • HTHidenori Tanimoto
    Hidenori Tanimoto
  • KSKiyoshi Sekiya
    Kiyoshi Sekiya
  • TTTakahiro Tsuburai
    Takahiro Tsuburai
  • HMHiroyuki Mitomi
    Hiroyuki Mitomi
  • KAKazuo Akiyama
    Kazuo Akiyama

Abstract
Aspirin-induced asthma (AIA) is a severe and difficult-to-treat allergic disease in which acute asthma attacks are induced by nonsteroidal anti-inflammatory drugs. Patients with AIA rarely experience asthma attacks when taking celecoxib, a specific inhibitor of cyclooxygenase (COX) 2. A 33-year-old woman had a severe asthma attack with hypoxia and lost consciousness after oral provocation testing with 15 mg of aspirin and also with 50 mg of celecoxib. After 2 months of treatment with 10 mg/day of oral prednisolone, 1600 μg/day of inhaled fluticasone propionate, montelukast as a leukotriene receptor antagonist (LTRA), and long-term beta-agonist, we again challenged her with a provocation test with up to 200 mg of celecoxib; this time there were neither allergic symptoms nor decrease in forced expiratory volume in 1 second. Patients with severe or poorly controlled asthma may experience asthma attacks even if using selective COX-2 inhibitors. However, treatment with steroids and an LTRAs may inhibit asthma attacks induced by celecoxib.